When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …

Mycophenolic acid (MPA), the active immunosuppressant form of the pro‐drug
mycophenolate mofetil (MMF), is a widely used component of immunosuppressive regimens …

BACKGROUND Pharmacokinetic monitoring of cyclosporine and tacrolimus, with the aim of
achieving adequate immunosuppression with minimized risk of graft rejection or toxicity, has …

Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.
Background Steroids have been shown to induce the hepatic glucuronyltransferase (GT) …

Background: Mycophenolate mofetil (MMF) has proven to be a very effective drug for the
prevention of acute rejection following renal transplantation when dosed as prescribed at 2 …

Background: Significant relationships between the mycophenolic acid (MPA) area under the
concentration–time curve (AUC0–12h) and the risks for acute rejection and side effects have …